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Abstract
The Whole Genome Sequencing Project initiated by The Hospital for Sick Children of Toronto intends 
to enroll patients between 1 to 18 years of age with congenital heart disease to test genome sequencing 
methods for personalized diagnoses and treatments. Twenty-five patients were randomly selected to 
be observed for their consent rate to the project based on factors of age, gender, ethnicity, presence of 
heart diseases in the patient’s family, and the type of congenital heart disease represented. Our studies 
found that females and ethnicities not of European descent, considered to be part of minority groups, 
were generally under-represented and had lower consent rates. There were no significant correlations 
between consent rates and familial history of heart disease, type of heart disease and age groups. These 
findings can aid in future studies conducted by the SickKids Hospital by indicating which patients may 
have higher consent rates and by raising inclusivity of minority groups to alleviate bias in medical studies.
Le Projet de Séquençage du Génome Entier initié par l’Hospital for Sick Children » de Toronto a l’intention de s’inscrire 
des patients âgés de 1 à 18 ans souffrant d’une cardiopathie congénitale pour tester les méthodes de séquençage  
du génome pour des diagnostics et des traitements personnalisés. Vingt-cinq patients ont été sélectionnés au hasard 
pour observer leur taux de consentement au projet en fonction des facteurs d’âge, de sexe, d’origine ethnique,  
de présence de maladies cardiaques dans la famille du patient et du type de cardiopathie congénitale représenté.  
Nos études ont montré que les femmes et les groupes ethniques d’origine non-européenne, considérés comme 
faisant partie de groupes minoritaires, étaient généralement sous-représentés et avaient des taux de consentement 
plus bas. Il n’y avait pas de corrélation significative entre les taux de consentement et les antécédents familiaux de  
maladie cardiaque, le type de maladie cardiaque et l’âge. Ces résultats peuvent aider dans les futures études conduit 
par L’Hospital SickKids en indiquant de comprendre quels patients pourraient avoir des taux de consentement plus 
élevés et d’aider à l’inclusion des groupes minoritaires pour atténuer le préjugé dans les études médicales.
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Introduction
What is Congenital Heart Disease?
Congenital heart disease is defined as genetic 
inheritance of one or more genotypic heart 
disease alleles inherited through one or both 
parents (Andelfinger, 2014), detrimentally affecting 
children around the world. The rates of such 
disorders have increasingly caught the attention 
of clinicians, prompting interest in improving 
predictions of an offspring inheriting the disease. 
If successful, the understanding and reduction of 
pediatric congenital heart diseases could not only 
allow for the healthcare system to better address 
the needs of patients and their families, but also 
for the earlier commencement of treatments, 
thus reducing the chance of passing on the allele 
to the next newborn (Hannah-Shmouni, 2015). 
One testing method that is widely recognized for 
identifying genetic variants potentially implicated 
in congenital heart disease, is Whole Genome 
Sequencing (WGS).
Whole Genome Sequencing
Over the last decade, there have been great 
advancements in genomic technologies, including 
WGS. This technology has enabled practitioners  
to identify potential genetic variants implicated  
in various genetic conditions, which has allowed 
for a better understanding of genetic makeup of 
the parent and offspring (Bowdin et. al, 2015).  
By identifying hidden genome markers and other 
underlying causes of the patient’s genetic makeup, 
the tool has allowed for the typical user to better 
acknowledge the contributing causes for present 
disorders, as well as earlier preparation and the 
prevention of possible diseases suggested by 
the readings from the procedure (Blue et. al, 
2014). Recently, the cost of WGS has drastically 
decreased and the use of this tool in clinics has 
increased (van El et. al, n.d.).
Although the clinical utility of this tool 
has advantages, it is also accompanied by 
complications. For example, it is vital to give the 
family an appropriate amount of time to make a 
decision on whether or not they will give consent, 
along with counseling from a professional  
before final agreements are made. The resources 
required for the hospital to implement counseling 
methods and staff personnel to advise the patient 
and their family may be tremendous, not to 
mention the scientists that are hired to sequence  
the genomes in the lab once the project is 
underway. Counseling and decision periods may  
take as long as the patient desires, making the 
exact amount of time and resources needed for 
this study difficult to predict. Moreover, it must be 
stressed in counseling that one must understand 
that not all information obtained from this test 
is completely accurate; false positives and/or 
negatives are possible (Berg, J. S., Khoury,  
M. J., Evans, J. P., 2011). Patients and their families 
should also be informed of secondary information 
that does not relate to the topic of congenital 
heart diseases but provides insight into other 
possible genetic disorders (Bowdin et. al, 2015). 
This is in addition to the discussion on the types 
of alleles that patients wish to be disclosed and 
other genetic information that are used only by  
the clinician(s) for the purpose of WGS study. 
These decisions are approached through 
counseling with one or more healthcare 
professionals responsible for addressing 
advantages and risks possible to the technology.
Our Aim
The goal of this study is to analyze and 
understand the reasons why a cohort of  
patients and/or their family will or will not  
decline the offer to participate in this project. 
Randomly chosen families and patients and  
their primary information are studied to 
determine if there is a pattern amongst those 
who have similar backgrounds. By performing  
this investigation, we may be able to understand 
how one’s medical background may correspond  
to their willingness to accept WGS, improve the 
techniques and approaches for patients who  
are less willing, and ultimately decrease bias  
and increase diversity in the study.
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Methods and Procedures
Population and Data Collection
Patients between the ages of 1-18 were  
recruited from the Division of Cardiology at  
The Hospital for Sick Children over a 4-month 
period (September 2016 to December 2016). 
Patients and their parents were eligible to  
participate in the study only if the patients  
had a primary cardiac diagnosis and were  
fluent in English. Data was initially obtained 
through verbal consultations then collected 
through electronic medical records. The 25 
patients in this study were randomly selected  
out of all the patients approached in the 
Cardiology Clinic.
This study was approved by the Research 
Ethics Board at The Hospital for Sick Children 
and informed consent was obtained from all 
participants.
Covariates
The data from 25 patients was taken,  
and all personal information including the 
participants name and contact information  
was removed. Data is shown for all patients  
and families approached including the gender  
(male, female, and unidentified), and ethnicity 
(European, Asian, African, Hispanic, and patients 
with two or more ethnicities). There was a total 
of seven types of congenital heart diseases 
represented in the approached patients:  
Pulmonary Stenosis, Atrial Septal Defect, 
Tetralogy of Fallot, Hypoplastic Left Heart 
Syndrome, Heterotaxy, Dilated Cardiomyopathy, 
and Transposition of Great Arteries. Finally,  
the data included whether consent was given by 
the individuals to participate in the procedure.
Statistical Analysis
The data were graphed, and characteristics 
were observed by comparing consent rates to 
their respective factors. To further analyze this 
information, the characteristics were compared 
with the Chi-squared test to evaluate the statistical 
significance between the characteristics of the 
patients – age, gender, ethnicity, presence of 
familial congenital and the type of congenital 
heart disease – and the rate of consent to WGS. 
The percentage of patients who consented to 
WGS compared to the total number of patients 
listed under each of the characteristics was 
calculated. The age category was further divided 
into four sub-groups to improve the interpretation 
of the averages of consent rates, which were 
taken from each of the four sub-groups.
Since a large portion of the study’s participants 
were of European ancestry, separate calculations 
were conducted on this subset of the sample. 
They are compared to the same categories 
created for all 25 patients (gender, age group, 
type of congenital heart disease and previous 
familial history) to compare the predominant 
ethnic group to other minorities of this study.
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100% Figure 1: Percent Consent Rate by Patient 
Ethnicity: Analysis of data on the represented 
ethnicities of the approached patients and the 
chance of consent are shown in percentages. 
The African ancestry had a ratio of 0:1 given 
consent to total number of patients. The Asian 
ancestry had a ratio of 2:3 given consent.  
The European ancestry has a ratio of 13:18.  
The Hispanic ancestry had a ratio of 0:1. 
The subgroup of patients with two or more 
ethnicities had a ratio of 1:2.
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100% Figure 2: Previous Family History of 
Congenital Heart Disease Compared to Rate 
of Consent/Denial to SickKids Genome Project 
68.75% of the subgroup with a pre-existing 
familial history provided consent. 66.67% of 
the subgroup without a pre-existing familial 
history of a congenital heart disease(s) 
provided consent to the SickKids Genome 
Project. The Chi-squared statistic is 0.0115. 
The p-value is 0.914641. This result is not 
significant at p < 0.05.
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100% Figure 3: Consent Rate Compared to Gender 
of Patients: Male patients (12) have a consent 
rate of 83.33% (10). Female patients (12) have 
a consent rate of 58.33% (7). The patient 
that is not specified has a 0% chance of 
consent. The Chi-squared statistic is 1.8151. 
The p-value is 0.177895. The result is not 
significant at p < 0.05.
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Figure 4: Type of Congenital Heart Disease of Approached Patients Compared to Consent Rate: 
Patients with Transposition of Great Arteries have a consent rate of 100%. Patients with Dilated 
Cardiomyopathy have a consent rate of 66.67%. Patients with heterotaxy have a consent rate of 
50%. Patients with Hypoplastic Left Heart Syndrome have a consent rate of 100%. Patients with 
Tetralogy of Fallot have a consent rate of 80%. Patients with Atrial Septal Defect have a consent 
rate of 20%. Patients with Pulmonary Stenosis have a consent rate of 60%.
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Figure 5: Age Groups of Approached Patients Compared to Consent Rate: Toddlers (ages 1-3) 
have a consent rate of 75%. Preschoolers (ages 4-5) have a consent rate of 66.67%. Grade-
schoolers (ages 6-12) have a consent rate of 70%. Teenagers (ages 13-18) have a consent rate  
of 71.43%. The Chi-squared statistics, when calculated with age groups 1-5 and 6-18, is 0.0017.  
The p-value is 0.967162. This result is not significant at p < 0.05.
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We have observed that 17 out of the 25 patients 
approached for participation in the SickKids 
Genome Clinic project gave consent. This places 
the initial consent rate, without the influence of 
other factors, at 68.00%.
Figure 1 illustrates the consent rate in terms 
of ethnicity including all 25 of the approached 
patients. The majority of patients were of 
European descent (18), followed by patients  
of Asian (3), mixed race (2), African (1) and 
Hispanic (1) ancestry. 13 out of 18 patients of 
European ancestry agreed to participate (76%), 
which have made them the highest consenting 
group. Two out of three patients (67%) of Asian 
ancestry gave consent. Half of the patients (50%) 
of more than one ethnicity (mixed race) gave 
consent, while patients of African and Hispanic 
ancestry did not provide consent at all. The mean 
consent rate calculated for all ethnicities was 
38.58%. The compared consent rates between 
European and non-European individuals were 
insignificant according to the Chi-squared test  
(p= 0.16962, p < 0.5).
We also analyzed the relationship between 
familial history of congenital heart conditions 
and consent (Figure 2). In this category, 16 of 
the 25 approached patients had a familial history 
of congenital heart disease(s), and 69.75% (11) 
of those patients gave consent to the SickKids 
Genome project. Two-thirds (6) of the patients 
that did not have a familial record of congenital 
heart disease(s) (9) also provided consent to the 
study. A Chi-squared test found no statistical 
significance between the presence of familial 
congenital heart disease and providing consent 
(p= 0.914641).
Of the 25 patients, 12 were male, 12 were female,  
and one patient was unspecified. Male patients 
had a higher consent rate at 83.33%, while 
females had a lower consent rate, with only 
58.33% agreeing to become a part of the 
Genome Clinic project. The patient who was  
not identified as either male or female did not 
provide consent. The Chi-squared was used 
to compare male and female patients consent 
rates, resulting in a value of 1.8151, with a p-value 
of 0.177895. The result was not statistically 
significant at p < 0.05.
Figure 5 explores the relationship between 
type of disease and the consent rate. Seven 
types of congenital heart disease are presented 
in this figure. More than half of the patients 
with conditions of Pulmonary Stenosis, Dilated 
Myocardiopathy, Tetralogy of Fallot, Hypoplastic 
Left Heart Syndrome, and Transposition of  
Great Arteries provided consent to the test.  
All five patients exhibiting Transposition of Great 
Arteries and the three patients with Hypoplastic 
Left Heart Syndrome also provided consent 
to the Genome project. Two of three patients 
exhibiting Dilated Myocardiopathy provided 
consent. A total of five patients exhibited 
Pulmonary Stenosis, three of which provided 
consent to the test. Less than half of the patients 
with either Heterotaxy or Atrial Septal Defect 
provided consent rate.
The ages of approached patients range from  
1 to 18 years old. Due to the broad range of 
ages represented, four age groups were formed 
in order to better analyze patterns of consent 
between similar ages. Groups are loosely 
formed based on typical preschool kindergarten, 
elementary, and high school ages in North America. 
The toddler group, ages 1 to 3, were represented 
by a total of four patients, with 3 out of 4 patients 
who provided consent. Patients aged four and 
five are placed in the preschool group, with a 
total of three patients in that group, and two 
providing consent. Patients in the grade school 
group were 6 to 12 years of age, with ten patients 
in this category, with a consent rate of 70.00%. 
The last group, teenagers, consisted of patients 
aged 13 to 18, was represented by seven patients 
with 71.43% consenting to the test. The age groups 
ranked from highest to lowest according to their 
respective consent rates are: Toddler, Teenager, 
Grade School, and Preschool.
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Referring back to Figure 1, patients of European 
descent have the highest consent rate of the 
five ethnic groups and is the dominant ethnicity 
represented by the sample – 13 of the total 25 
approached families. Therefore, separate charts 
were created to test for possible patterns of 
consent rates with only patients of European 
descent, accounting for factors such as gender. 
There were a total of 9 male patients and 8 female 
patients, with 77.78% (7) and 50.00% (4) consent 
rates, respectively. The Chi-squared was used to 
compare these results and found no statistical 
significance (p= 0.231605).
All patients of European descent with Hypoplastic 
Left Heart Syndrome and Transposition of Great 
Arteries provided consent. Patients in this category 
with Tetralogy of Fallot ranked second in providing 
consent. Patients with Pulmonary Stenosis and 
Dilated Myocardiopathy were ranked third, and 
patients with Heterotaxy were ranked fourth in 
provided consent. No patients with Atrial Septal 
Defect provided consent to the genome project.
Discussion
The future application of WGS in providing 
personalized medicine is an important 
advancement in healthcare. The WGS project 
performed by the Hospital for Sick Children 
attempted to recruit patients with existing 
congenital heart diseases to participate in a 
genome study to test the advantages of using 
WGS for medicine and the factors that may  
cause patients to reject or accept the procedure. 
Though participation is free of charge and  
the resulting information may be valuable,  
some families did not give consent. It is  
important to understand the reasoning behind 
such decisions and this study attempted to do  
so by analyzing the factors provided in the 
patient’s profile from SickKids Hospital. If a 
pattern in consent rate and these factors can  
be found, it will enable hospital staff to develop 
new methods to work with those patients who  
are less likely to provide consent.
Ethnicity
Ethnicity is perhaps one of the most interesting 
factors to analyze since one ethnicity is repre-
sented by the majority of patients, whereas the 
remaining ethnicities only represent a small 
portion of the sample. It was observed that the 
patients of European descent had the highest 
consent rate, when compared to patients of  
Asian, African, Hispanic, or two or more ethnicities. 
However, the differences in consent rates by 
ethnicity were not statistically significant.  
Though the sample is ethnically diverse, only 
patients who are fluent in English were approached 
and those with the potential to require a translator 
were excluded. This places Europeans – most with 
English as their first language – in the majority of 
all the approached patients. This finding suggests 
that further efforts should be made to provide 
equal chances of participation in scientific studies 
to patients who do not have English as their first 
language. Not only will this promote equity in the 
sample of patients that are often provided less 
opportunities, but also decrease potential biases  
in this study towards certain races or cultures.
A comparison can be made to another study 
that highlighted the reasons why consent rates 
are lower for ethnicities other than the European 
ancestry. In Wendler’s study, a comprehensive 
literature search was conducted on 20 health 
research papers that reported enrollment rates 
due to race or ethnicity (Wendler et. al, 2005).  
It was found that patients representing ethnicities 
in the minority were willing to participate only  
if they were eligible and invited to participate,  
not because they had a lower consent rate 
compared to the dominant ancestry (Wendler  
et. al, 2005). Hispanics and African-Americans 
agreed to participate more than Europeans,  
but the differences in consent rates between  
the European ancestry and the other ethnicities  
were minimal (Wendler et. al, 2005). Wendler 
lends further evidence that past speculated 
theories of historic abuse leading to mistrust  
of scientific studies from minority ethnicities  
in North America are false; however, another  
study found that Europeans were more likely  
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to provide consent (Street et. al, n.d.). Though  
the procedures of these studies and the targeted 
population differ drastically from the WGS study, 
commonalities were found in the explanations 
with regards to low participation rates. They all 
address the fact that low consent rates were 
not by chance; instead, it may be due to other 
underlying causes such as exposure of a race  
to scientific opportunities or faults in history  
that have caused certain groups to remain 
doubtful of experimental studies.
Comparatively, other studies observed significant 
differences in the consent rates of Europeans and 
other minority groups. In correspondence to the 
findings in the present study and in Street et al. 
(Street et. al, n.d.), there were more Europeans 
than minority ethnicities giving consent to parti-
cipation in medical studies (Mucsi et. al, 2017). 
This may also be due to the European ancestry 
dominating 54% of approached sample size.
The research on the rates of participations 
amongst African American populations in  
North American health studies indicates 
that African Americans always had a lower 
participation rate since more Europeans are 
approached. African Americans are often 
excluded as well due to language barriers  
in complex medical surveys and studies (Street 
et. al, n.d.). When asked what their feelings were 
towards medical studies, many have referred  
to the Tuskegee Syphilis Study – a medical study 
that has been ridiculed for its unethical practices 
(Reverby, S. M., 2017). The participants were in 
fear of being “guinea pigs” and did not want the 
potential to become infected or to be injected 
with a virus via needles. Another famous example 
may be from the case of Henrietta Lacks who 
had her biopsy of tumour cells taken and grown 
in a lab without her or her family’s permission. 
Though her cells were the first to successfully 
grow and contributed to the polio vaccine, the 
discovery of human telomerase, and countless 
other advances, it was an unethical approach. 
An adequate response on what was done to the 
biopsy was answered 30 years after the incident 
(Callaway, E., 2013). Furthermore, research with 
African-American participants is limited due 
to racial discrimination and poverty, and since 
the study will not directly benefit the African 
American population, participation is seen as  
a waste of time (Corbie-Smith et. al, 1999).
In addition to ethnicity, a history of familial 
congenital heart disease can affect decisions of 
participation due to fear of unknown outcomes 
from genome sequencing or poor experiences  
with past medical studies. In this study, the differ-
ences between the two groups of patients were 
not significant (3.08% difference, p= 0.914641).  
There are currently not many studies targeting 
the participation rates of patients in research 
studies that can provide reasoning for this 
finding. It can be hypothesized that patients 
with a previous family history of heart disease 
are more motivated to participate in the study 
since they are eager to learn about the potential 
underlying cause of their disease. Without pre-
vious exposure to risks of heart diseases, the group 
with no familial records may not see the benefits 
of the study and therefore may not have provided 
consent to participating due to that reason. 
However, further research is needed to ascertain 
the reason(s) why there were no significant 
differences between the two groups.
When the European ancestry was included with 
the same factors (age, gender, familial history,  
type of disease) compared to participation rate, 
the results were similar to comparisons made 
amongst the entire sample of patients. Though 
statistically insignificant, the percentage of 
females providing consent to the genome project 
was lower than males of Europeans descent 
(consent rates 77.78% males, 50.00% females.  
P= 0.231605). This finding was supported by a 
study performed by Street et al. (2005), where they  
found more women expressed negative concerns 
about scientific studies than men but contradicts 
a consent rate study performed on a sample of 
25,000 by Dunn et al. (Dunn, K. M., 2004) stating 
that men before 59 had a lower consent rate than 
women in the same age range. Further analysis 
was performed on the types of heart disease 
and age group, and the findings were similar to 
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the data found for the complete sample. These 
findings may suggest that even though patients 
of European descent may be more represented 
and have a higher consent rate, ethnicity may not 
be strongly influential in the likelihood for certain 
genders or age groups to give consent.
Gender
Furthermore, gender plays a role when deter-
mining the likelihood of participation in medical 
studies (Murthy, V. H., Krumholz, H. M., Gross, C. 
P., n.d.). Though statistically insignificant when 
placed into the Chi-squared test, 25% more males  
gave consent to participate in a study rather than 
females (consent rates 83.33% male, 58.33% 
female, p= 0.177895). Of note, sex preference  
is found to be a function of age, for example,  
30 to 60-year-old men and women had an 
equally likely chance of providing consent, 
whereas older men (60+ years) tend to have 
a noticeably higher consent rate than women 
(Murthy, V. H., Krumholz, H. M., Gross, C. P., n.d.). 
Even though the sample sizes and targeted 
purpose in Street and Stone’s studies differ to  
the current study, they may still explain the reason 
why less than 60% of female patients have given 
consent to the WGS study compared to over  
80% of male patients.
Similarly, a correlation may arise when looking at 
the effects of gender and race on consent rates. 
When a cancer clinical study was analyzed,  
more than one third of women of colour agreed 
that scientists cannot be trusted, while only  
4.1% of white women had the same belief 
(Mouton et. al, n.d.). Similar results were found 
in an AIDS Clinical Studies, stating that females 
are less likely to participate because most of 
the women in that cohort study were from 
communities of colour (Stone et. al, 1997).  
Of the four females in the WGS study that  
are of non-European background, three gave 
consent to the study and only one did not,  
while only half of European females gave 
consent. This may suggest that Mouton and 
Stone’s findings are not accurate for this sample. 
The statement cannot fairly represent the results  
of this genome study since the participants 
included only one more female patient than  
male that is not of European descent. Of the  
25 patients in the sample, one had an unidentified 
gender. Because the subject’s sexuality is 
unknown, he or she must be excluded from  
the analysis of gender versus participation.
Disease
On the other hand, this study’s results indicate 
that there were no differences in consent rates 
amongst the seven different heart diseases.  
The diseases cannot be ranked in order of 
severity since each type affects a different part 
of the circulatory system, nor could we determine 
to what degree the patients were being affected 
by their diseases without being provided more 
detailed information. While there has been  
some evidence that the type of disease will  
yield a different participation rate, specifically  
in cancer clinical trials (Mouton et. al, n.d.),  
there were few research studies on consent  
rates focusing specifically on patients with 
congenital heart diseases.
The three diseases with the lowest consent rates 
(Atrial Septal Defect, Heterotaxy, Pulmonary 
Stenosis) were represented by twelve patients,  
and characteristics of these patients were 
observed for this study. Nine of the patients  
were European, and only one of the latter three 
was African American. Research on consent  
rates of Europeans has previously found patients  
of the three diseases have higher consent rates.  
However, eight of the twelve patients were female; 
the gender considered to be a part of the minority 
in medical studies and is expected to have a 
lower consent rate than a group with more males. 
Further analysis showed that the remaining four 
diseases, with higher consent rates did match 
consent patterns found in previous research.  
Since most of these patients are male and/or 
European, consent rates were between 66.67% 
and 100%. Regardless, patients with any of the 
diseases had a low representation of people  
from minority ethnicities.
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Age
Since the genome project was performed at  
the SickKids Hospital, only children from birth 
to 18 years of age were approached, therefore 
the age range in this study does not accurately 
reflect findings from other studies that are 
focused on the adult population (Dunn, K. M., 
2004). Upon analysis, all four age groups had 
similar consent rates (Figure 5). This is likely 
because all patients approached are 18 years 
old or younger, thus it can be assumed that the 
decision for participation is made by the patient’s 
parent or guardian. As mentioned before, women 
and men ages 30 to 60 years of age have an 
equal chance of providing consent. So, if parents 
and guardians are near that age range, then the 
consent pattern would correlate with this finding. 
Moreover, age cannot be precise in determining 
consent rates regarding such a young age group. 
Parents may believe that participating may provide 
few to no benefits to the child and family members, 
which would limit their willingness to participate. 
Additionally, the SickKids WGS project is an early 
phase clinical trial. It did not provide families with 
information regarding the treatment(s) that can be 
determined through WGS, nor were the families 
offered any financial compensation. Due to these 
reasons, many may have seen the project as a 
waste of personal time, refusing to participate. 
Ultimately parental biases and preconceptions  
may have had an effect on patient consent,  
due to the young age of patients.
Limitations
Though the data collected are recent, the sample 
size may be too small to determine whether the 
differences were statistically significant. With a 
random sample of 25 patients, it is difficult to 
ascertain the strength of a relationship between 
two or more variables. Findings may continue 
to change as the sample grows larger. It is also 
difficult to apply findings in this study to other 
potential medical studies. The WGS Project 
performed at SickKids Hospital in Toronto is 
specifically targeted towards children under 
the age of 18 and is only open to those in the 
cardiology department. Other studies that require 
patients of all ages or those above 18 years of 
age will not be able to apply the findings in this 
study since clarity was not provided who made 
decisions of consent; the patient, or the parent/
guardian. Furthermore, this sample only represents 
seven congenital heart diseases in children.  
A larger sample with more diseases may be able 
to determine whether the type of defect has a 
correlation to consent rate, but otherwise the 
findings for this factor were inconclusive and  
were not considered reliable for application to 
other studies.
Based on the results of the study, some changes  
that can be made in the future are the represen-
tation of minorities in medical studies. A general  
pattern was observed when research was 
conducted showing that patients of African 
ancestry or of the female gender are less likely  
to be present in medical studies than patients  
of European descent and males. The under-
representation of minority groups (ex. gender 
and race) poses a bias in studies that hope to 
yield findings to benefit the general population. 
In the genome sequencing project, only families 
fluent in English were approached, placing those 
with language barriers in the minority. The same 
patients may also feel less welcome in scientific 
studies since they believe that racial discrimination 
will continue to exist and that their contributions 
will be minimal in medical advancements.  
Efforts can be made to allow patients of African 
descent to feel more inclusive, achieving a more 
accurate representation of the African population 
in Canada. Moreover, accommodations can be 
made by providing translators to those who are 
not fluent in English to account for the increasing 
number of immigrants from other countries. 
Further information can also be provided to 
female patients to boost participation of this 
gender to make the number of both genders  
as equal as possible. All of these suggestions  
are made in hopes that the WGS study can 
promote social equity to lessen biases linked  
to gender and age and to bridge the gaps that 
exist between different cultures and races.
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Conclusions
In conclusion, our results suggest the comparably 
low consent rates of female and/or patients 
representing ethnicities in the minority may be  
due to the underrepresentation of these groups in 
the initial sample, not because men or Europeans 
are more likely to participate in the WGS Project. 
The importance of factors such as age, familial 
history, as well as types of disease in understanding 
the likelihood of participation remains inconclusive 
as results yielded did not reach statistical 
significance. These outcomes highlight that while 
there are limitations to which patients meet the 
requirements to participate in this project,  
patients in minority groups should never be 
overlooked. A fair enrollment of all genders and 
ethnicities will result in more diverse opinions 
on advancing technology, helping to improve 
the health care system to benefit all members of 
the society. Moreover, there were no benefits in 
favoring one factor when deciding which patients 
will more likely provide consent; variance amongst 
patients highlights the diversity of our present-day 
culture and the need for a representative sample 
in medical studies. Ultimately, further research 
with a larger sample size will be needed to 
validate findings and conclusions.
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